Patent ID: 9469630
Filing Date: 2016-10-18
CPC Classification: A61K,A61P,C07D

Claim Text:
1. A composition comprising the following (1) to (5), (1) N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R, 2′S, 3′R, 4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof as an active ingredient, wherein the active ingredient is in crystal form, and the mean particle size of the crystal is about 4 μm - about 26 μm, (2) a surfactant comprising at least one ingredient selected from the group consisting of polysorbate 80, polysorbate 20, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188 and polyoxyethylene castor oil, (3) a buffer comprising at least one ingredient selected from the group consisting of sodium phosphate, disodium hydrogenphosphate, sodium dihydrogenphosphate, potassium phosphate, dipotassium hydrogenphosphate, potassium dihydrogenphosphate, trometamol, sodium carbonate, sodium bicarbonate, meglumine, arginine, triethanolamine and citric acid, (4) an isotonic agent comprising at least one ingredient selected from the group consisting of sodium chloride and D-mannitol, and (5) water for injection.